United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
2014_register
executive
2014-04-02
article
Determination of Regulatory Review Period for Purposes of Patent Extension; EYLEA
Notices
D09002ee1bdc5c5d5
D09002ee1bdc5c658
United States
Department of Health and Human Services
originator
org
United States Government Agency or Subagency
United States
Food and Drug Administration
originator
org
United States Government Agency or Subagency
The Food and Drug Administration (FDA) has determined the regulatory review period for EYLEA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.
79 FR 18566
https://www.govinfo.gov/app/details/FR-2014-04-02/2014-07333
2014-07333
fr02ap14-76
4160-01-P
Docket Nos. FDA-2012-E-0487
FDA-2012-E-0488
and FDA-2012-E-0489
https://www.govinfo.gov/app/details/FR-2014-04-02/2014-07333
https://www.govinfo.gov/content/pkg/FR-2014-04-02/html/2014-07333.htm
https://www.govinfo.gov/content/pkg/FR-2014-04-02/pdf/2014-07333.pdf
2 p.
18566
18567
79 FR 18566
Determination of Regulatory Review Period for Purposes of Patent Extension; EYLEA; Federal Register Vol. 79, Issue
NOTICE
2014-07333
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Docket Nos. FDA-2012-E-0487
FDA-2012-E-0488
and FDA-2012-E-0489
4160-01-P
2014-07333
Notice.
The Food and Drug Administration (FDA) has determined the regulatory review period for EYLEA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.
Beverly Friedman, Office of Management, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave. Bldg. 51, Rm. 6284, Silver Spring, MD 20993-0002, 301-796-3602.
Patent Extension Regulatory Review Periods:
EYLEA
,
http://www.regulations.gov
Federal Register
Vol. 79, no. 63
Office of the Federal Register, National Archives and Records Administration
2014-04-02
continuing
daily
deposited
born digital
180 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-2014-04-02
P0b002ee1881e73a2
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:fr02ap14
https://www.govinfo.gov/app/details/FR-2014-04-02
https://www.govinfo.gov/content/pkg/FR-2014-04-02/pdf/FR-2014-04-02.pdf
https://www.govinfo.gov/content/pkg/FR-2014-04-02/xml/FR-2014-04-02.xml
fdlp
18441
18610
DGPO
2014-04-02
2023-04-29
FR-2014-04-02
machine generated
eng
FR
FR-2014-04-02
79
63